Jun 27 2011
Bonovo® Orthopedics, Inc. announced today that it has formed Bonovo Recon™, a new division dedicated to accelerating the growth of Bonovo's hip and knee product development and sales initiatives. Bonovo Recon begins operations with a full line of hip and knee products for sale to the China orthopedic market.
Bonovo entered the joint reconstruction market in China in 2007 through the acquisition of Kangknow, Inc., a Tianjin-based hip company. In 2008, Bonovo partnered with Japan Medical Materials, Inc. (JMM) to bring a full line of imported hip and knee products to the Chinese market. Through the JMM partnership, Bonovo has introduced the first ceramic bi-surface knee system to China designed specifically for the Asian anatomy and lifestyle with improved knee flexion and durability. Bonovo's newly formed reconstruction division has a full pipeline of cemented and uncemented hips and knees undergoing clinical trials in China, as well as a product development and instrument design team located in Beijing.
According to Peter Slate, Bonovo's Chief Executive Officer, "Bonovo has developed one of the most comprehensive total joint design and development teams in China, along with a full pipeline line of products. The formation of Bonovo Recon provides Bonovo with a more focused platform to continue making investments in this exciting market."
With the formation of this the new division, Bonovo has added key personnel to its joint marketing and R&D teams and has reorganized its Sales Group to form a fully dedicated hip and knee sales team. Additionally, Bonovo has increased its joint reconstruction training efforts through the Bonovo Academic Alliance™, its organization dedicated to training and enhancing the connection between Eastern and Western surgeons.
According to Chip Bao, Bonovo's President of Asia, "The formation of Bonovo Recon solidifies Bonovo's commitment to provide customers throughout China with a complete portfolio of hip and knee products and a fully dedicated team committed to training and personal service. Through Bonovo Recon, we will continue to play a leadership role in improving patient care in the Chinese orthopedic market."